Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Current Assets (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Current Assets for 16 consecutive years, with $753.1 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 42.51% to $753.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $753.1 million through Dec 2025, up 42.51% year-over-year, with the annual reading at $753.1 million for FY2025, 42.51% up from the prior year.
  • Current Assets hit $753.1 million in Q4 2025 for Ani Pharmaceuticals, up from $698.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $753.1 million in Q4 2025 to a low of $182.8 million in Q1 2021.
  • Historically, Current Assets has averaged $437.1 million across 5 years, with a median of $478.3 million in 2023.
  • Biggest five-year swings in Current Assets: skyrocketed 88.92% in 2021 and later fell 0.79% in 2025.
  • Year by year, Current Assets stood at $321.8 million in 2021, then rose by 6.99% to $344.3 million in 2022, then skyrocketed by 50.99% to $519.8 million in 2023, then rose by 1.66% to $528.5 million in 2024, then skyrocketed by 42.51% to $753.1 million in 2025.
  • Business Quant data shows Current Assets for ANIP at $753.1 million in Q4 2025, $698.4 million in Q3 2025, and $602.6 million in Q2 2025.